The G53D Mutation in Kir6.2 (KCNJ11) Is Associated with Neonatal Diabetes and Motor Dysfunction in Adulthood that Is Improved with Sulfonylurea Therapy | Zendy

Joseph C. Koster | Zendy; Francesco Cadario | Zendy; Cinzia Peruzzi | Zendy; Carlo Colombo | Zendy; Colin G. Nichols | Zendy; Fabrizio Barbetti | Zendy

Open Access

The G53D Mutation in Kir6.2 (KCNJ11) Is Associated with Neonatal Diabetes and Motor Dysfunction in Adulthood that Is Improved with Sulfonylurea Therapy

Author(s) -

Joseph C. Koster,

Francesco Cadario,

Cinzia Peruzzi,

Carlo Colombo,

Colin G. Nichols,

Fabrizio Barbetti

Publication year - 2007

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2007-1826

Subject(s) - gliclazide , kir6.2 , glibenclamide , medicine , endocrinology , sulfonylurea receptor , diabetes mellitus , context (archaeology) , insulin , potassium channel , skeletal muscle , biology , protein subunit , genetics , gene , paleontology

Mutations in the Kir6.2 subunit (KCNJ11) of the ATP-sensitive potassium channel (KATP) underlie neonatal diabetes mellitus. In severe cases, Kir6.2 mutations underlie developmental delay, epilepsy, and neonatal diabetes (DEND). All Kir6.2 mutations examined decrease the ATP inhibition of KATP, which is predicted to suppress electrical activity in neurons (peripheral and central), muscle, and pancreas. Inhibitory sulfonylureas (SUs) have been used successfully to treat diabetes in patients with activating Kir6.2 mutations. There are two reports of improved neurological features in SU-treated DEND patients but no report of such improvement in adulthood.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research